|
[1]ADDISON T,GULL W.On a certain affection of the skin:vitiligoidea-alpha,plana,beta tuberosa[J].Guy's Hosp Rep,1851,7:265-276.
|
|
[2]Mac MAHON HE,THANNHAUSER SJ.Xanthomatous biliary cirrhosis:a clinical syndrome[J].Ann Intern Med,1949,30(1):121-179.
|
|
[3]SHERLOCK S.Primary billiary cirrhosis(chronic intrahepatic obstructive jaundice)[J].Gastroenterology,1959,37:574-586.
|
|
[4]BEUERS U,GERSHWIN ME,GISH RG,et al.Changing nomenclature for PBC:from‘cirrhosis’to‘cholangitis’[J].Hepatology,2015,62(5):1620-1622.
|
|
[5]LIU C,XU CY,LI GD,et al.Analysis of clinical features of patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome[J].J Jilin Univ:Med Edit,2014,40(3):646-649.(in Chinese)刘晨,徐长妍,李国东,等.自身免疫性肝炎/源发性胆汁性肝硬化重叠综合征患者临床特征分析[J].吉林大学学报:医学版,2014,40(3):646-649.
|
|
[6]BOONSTRA K,BEUERS U,PONSIOEN CY.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:a systematic review[J].J Hepatol,2012,56(5):1181-1188.
|
|
[7]GRIFFITHS L,DYSON JK,JONES DE.The new epidemiology of primary biliary cirrhosis[J].Semin Liver Dis,2014,34(3):318-328.
|
|
[8]WATSON RG,ANGUS PW,DEWAR M,et al.Low prevalence of primary biliary cirrhosis in Victoria,Australia.Melbourne Liver Group[J].Gut,1995,36(6):927-930.
|
|
[9]SMYK DS,RIGOPOULOU EI,BOGDANOS DP.Potential roles for infectious agents in the pathophysiology of primary biliary cirrhosis:what's new?[J].Curr Infect Dis Rep,2013,15(1):14-24.
|
|
[10]MANTAKA A,KOULENTAKI M,CHLOUVERAKIS G,et al.Primary biliary cirrhosis in a genetically homogeneous population:disease associations and familial occurrence rates[J].BMC Gastroenterol,2012,12:110.
|
|
[11]CORPECHOT C,CHRETIEN Y,CHAZOUILLERES O,et al.Demographic,lifestyle,medical and familial factors associated with primary biliary cirrhosis[J].J Hepatol,2010,53(1):162-169.
|
|
[12]BEUERS U,TRAUNER M,JANSEN P,et al.New paradigms in the treatment of hepatic cholestasis:from UDCA to FXR,PXR and beyond[J].J Hepatol,2015,62(1 Suppl):s25-s37.
|
|
[13]Chinese Society of Hepatology,Chinese Medical Association,Chinese Society of Gastroenterology,Chinese Medical Association,Chinese Socitety of Infctious,Chinese Medical Associety.Consensous on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J].J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J].临床肝胆病杂志,2015,31(12):1980-1988.
|
|
[14]YAMAGIWA S,KAMIMURA H,TAKAMURA M,et al.Autoantibodies in primary biliary cirrhosis:recent progress in research on the pathogenetic and clinical significance[J].World J Gastroentero,2014,20(10):2606-2612.
|
|
[15]NAKAMURA M.Clinical significance of autoantibodies in primary biliary cirrhosis[J].Semin Liver Dis,2014,34(3):334-340.
|
|
[16]INVERNIZZI P,SELMI C,RANFTLER C.et al.Antinuclear antibodies in primary biliary cirrhosis[J].Semin Liver Dis,2005,25(3):298-310.
|
|
[17]IMAM MH,LINDOR KD.The natural history of primary biliary cirrhosis[J].Semin Liver Dis,2014,34(3):329-333.
|
|
[18]DENG HM,HU SL,CHEN WX,et al.Meta-analysis of antiGP210 antibody and anti-SP100 antibody detection for diagnosis of primary biliary cirrhosis[J].Chin J Hepatol,2016,24(1):62-68.(in Chinese)邓红梅,胡世玲,陈维贤,等.抗核孔膜蛋白和抗核体蛋白抗体对原发性胆汁性肝硬化诊断价值的meta分析[J].中华肝脏病杂志,2016,24(1):62-68.
|
|
[19]MITCHISON HC,BASSENDINE MF,HENDRICK A,et al.Positive antimitochondrial antibody but normal alkaline phosphatase——is this primary biliary cirrhosis?[J].Hepatology,1986,6:1279-1284.
|
|
[20]SILVEIRA MG,TALWALKAR JA,ANGULO P,et al.Overlap of autoimmune hepatitis and primary biliary cirrhosis:long-term outcomes[J].Am J Gastroenterol,2007,102(6):1244-1250.
|
|
[21]TAN S,MOVAHEDI Z,BEISEL J,et al.Correlation of anti-mitochondrial antibodies with liver histology and outcomes[J].Dig Dis Sci,2016,61(6):1770-1771.
|
|
[22]LINDGREN S,GLAUMANN H,ALMER S,et al.Transitions between variant forms of primary biliary cirrhosis during long-term follow-up[J].Eur J Intern Med,2009,20(4):398-402.
|
|
[23]JULIUSSON G,IMAM M,BJORNSSON ES,et al.Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis[J].Scand J Gastroenterol,2016,51(6):745-752.
|
|
[24]HIRSCHFIELD GM,HEATHCOTE EJ.Antimitochondrial antibody-negative primary biliary cirrhosis[J].Clin Liver Dis,2008,12(2):323-331;viii-ix.
|
|
[25]PARES A,CABALLERIA L,RODES J.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid[J].Gastroenterology,2006,130(3):715-720.
|
|
[26]ter BORG PC,SCHALM SW,HANSEN BE,et al.Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis.Results of a 10-yr cohort study involving 297 patients[J].Am J Gastroenterol,2006,101(9):2044-2050.
|
|
[27]POUPON RE,LINDOR KD,CAUCH-DUDEK K,et al.Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis[J].Gastroenterology,1997,113(3):884-890.
|
|
[28]ABBAS G,LINDOR KD.Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid[J].Expert Opin Pharmacother,2010,11(3):387-392.
|
|
[29]KUIPER EM,HANSEN BE,ADANG RP,et al.Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid[J].Eur J Gastroenterol Hepatol,2010,22:1495-1502.
|
|
[30]CUPERUS FJ,HALILBASIC E,TRAUNER M.Fibrate treatment for primary biliary cirrhosis[J].Curr Opin Gastroenterol,2014,30(3):279-286.
|
|
[31]HONDA A,IKEGAMI T,NAKAMUTA M,et al.Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid[J].Hepatology,2013,57(5):1931-1941.
|
|
[32]HAN XF,WANG QX,LIU Y,et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy[J].J Dig Dis,2012,13(4):219-224.
|
|
[33]GRIGORIAN AY,MARDINI HE,CORPECHOT C,et al.Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis:a meta-analysis[J].Clin Res Hepatol Gastroenterol,2015,39(3):296-306.
|
|
[34]YIN Q,LI J,XIA Y,et al.Systematic review and meta-analysis:bezafibrate in patients with primary biliary cirrhosis[J].Drug Des Devel Ther,2015,9:5407-5419.
|
|
[35]TSUDA M,MORITOKI Y,LIAN ZX,et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology,2012,55(2):512-521.
|
|
[36]MYERS RP,SWAIN MG,LEE SS,et al.B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J].Am J Gastroenterol,2013,108(6):933-941.
|
|
[37]YIN YF,ZHANG X.B cell depletion in treating primary biliary cirrhosis:pros and cons[J].World J Gastroenterol,2012,18(30):3938-3940.
|
|
[38]HIRSCHFIELD GM,LIU X,XU C,et al.Primary biliary cirrhosis associated with HLA,IL12A,and IL12RB2 variants[J].N Engl J Med,2009,360(24):2544-2555.
|
|
[39]HIRSCHFIELD GM,GERSHWIN ME,STRAUSS R,et al.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid:a proof-of-concept study[J].Hepatology,2016,64(1):189-199.
|
|
[40]HIRSCHFIELD GM,MASON A,LUKETIC V,et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology,2015,148(4):751-761,e758.
|
|
[41]TRIVEDI PJ,HIRSCHFIELD GM,GERSHWIN ME.Obeticholic acid for the treatment of primary biliary cirrhosis[J].Expert Rev Clin Pharmacol,2016,9(1):13-26.
|
|
[42]ALI AH,TABIBIAN JH,CAREY EJ,et al.Emerging drugs for the treatment of primary biliary cholangitis[J].Expert Opin Emerg Drugs,2016,21(1):39-56.
|
|
[43]RAUTIAINEN H,KARKKAINEN P,KARVONEN AL,et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology,2005,41(4):747-752.
|
|
[44]WANG L,HAN Q,CHEN H,et al.Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis[J].Stem Cells Dev,2014,23(20):2482-2489.
|
|
[45]WANG L,LI J,LIU H,et al.Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis[J].J Gastroenterol Hepatol,2013,28(Suppl 1):85-92.
|
|
[46]DU Y,FANG L.Clinical efficacy of traditional Chinese medicine/herbal decotion combined with ursodeoxycholic acid for primary biliary cirrhosis:a meta-analysis[J].J Clin Hepatol,2015,31(1):68-73.(in Chinese)杜莹,方蕾.中药汤剂/中成药联合熊去氧胆酸治疗原发性胆汁性肝硬化疗效的meta分析[J].临床肝胆病杂志,2015,31(1):68-73.
|
|
[47]REN M,ZHENG YJ,ZHU JF.TCM syndrome differentiation type of primary biliary cirrhosis[J].Jilin J Tradit Chin Med,2016,36(7):678-681.(in Chinese)任朦,郑亚江,祝峻峰.原发性胆汁性胆汁性肝硬化中医辨证分型[J].吉林中医药,2016,36(7):678-681.
|
|
[48]POUPON R.Evidence-based treatment of primary biliary cirrhosis[J].Dig Dis,2014,32(5):626-630.
|
|
[49]LEUNG J,BONIS PA,KAPLAN MM.Colchicine or methotrexate,with ursodiol,are effective after 20 years in a subset of patients with primary biliary cirrhosis[J].Clin Gastroenterol Hepatol,2011,9(9):776-780.
|
|
[50]RACZYNSKA J,HABIOR A,PACZEK L,et al.Primary biliary cirrhosis in the era of liver transplantation[J].Ann Transplant,2014,19:488-493.
|
|
[51]European Association for the Study of the Liver.EASL clinical practice guidelines:management of cholestatic liver diseases[J].J Hepatol,2009,51(2):237-267.
|
DownLoad: